Respiratory Syncytial Virus (RSV) Therapeutics Market: How Are...

agregó una foto Health

2026-07-09 10:38:54 -

Respiratory Syncytial Virus (RSV) Therapeutics Market: How Are Long-Acting Monoclonal Antibodies Transforming Infant Protection?

Long-acting RSV monoclonal antibodies in infant prophylaxis — the single-injection passive immunization (nirsevimab/Beyfortus) providing five-month protection against RSV lower respiratory tract disease in all infants regardless of gestational age or health status representing the most significant preventive advance in pediatric infectious disease — create the most universally...

0 Commentarios 0 Acciones 24 Views 0 Vista previa